Literature DB >> 33277241

Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.

Grant S Schulert1,2, Alex V Pickering3, Thuy Do4, Sanjeev Dhakal4, Ndate Fall4, Daniel Schnell5, Mario Medvedovic2, Nathan Salomonis2,5, Sherry Thornton4,2, Alexei A Grom4,2.   

Abstract

OBJECTIVES: Systemic juvenile idiopathic arthritis (SJIA) confers high risk for macrophage activation syndrome (MAS), a life-threatening cytokine storm driven by interferon (IFN)-γ. SJIA monocytes display IFN-γ hyper-responsiveness, but the molecular basis of this remains unclear. The objective of this study is to identify circulating monocyte and bone marrow macrophage (BMM) polarisation phenotypes in SJIA including molecular features contributing to IFN response.
METHODS: Bulk RNA-seq was performed on peripheral blood monocytes (n=26 SJIA patients) and single cell (sc) RNA-seq was performed on BMM (n=1). Cultured macrophages were used to define consequences of tripartite motif containing 8 (TRIM8) knockdown on IFN-γ signalling.
RESULTS: Bulk RNA-seq of SJIA monocytes revealed marked transcriptional changes in patients with elevated ferritin levels. We identified substantial overlap with multiple polarisation states but little evidence of IFN-induced signature. Interestingly, among the most highly upregulated genes was TRIM8, a positive regulator of IFN-γ signalling. In contrast to PBMC from SJIA patients without MAS, scRNA-seq of BMM from a patient with SJIA and MAS identified distinct subpopulations of BMM with altered transcriptomes, including upregulated IFN-γ response pathways. These BMM also showed significantly increased expression of TRIM8. In vitro knockdown of TRIM8 in macrophages significantly reduced IFN-γ responsiveness.
CONCLUSIONS: Macrophages with an 'IFN-γ response' phenotype and TRIM8 overexpression were expanded in the bone marrow from an MAS patient. TRIM8 is also upregulated in SJIA monocytes, and augments macrophage IFN-γ response in vitro, providing both a candidate molecular mechanism and potential therapeutic target for monocyte hyper-responsiveness to IFNγ in cytokine storms including MAS. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; cytokines; inflammation; juvenile

Year:  2020        PMID: 33277241     DOI: 10.1136/annrheumdis-2020-217470

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

Review 1.  Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).

Authors:  Emely L Verweyen; Grant S Schulert
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.046

2.  Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases - a proof of concept study.

Authors:  My Kieu Ha; Esther Bartholomeus; Luc Van Os; Julie Dandelooy; Julie Leysen; Olivier Aerts; Vasiliki Siozopoulou; Eline De Smet; Jan Gielen; Khadija Guerti; Michel De Maeseneer; Nele Herregods; Bouchra Lechkar; Ruth Wittoek; Elke Geens; Laura Claes; Mahmoud Zaqout; Wendy Dewals; Annelies Lemay; David Tuerlinckx; David Weynants; Koen Vanlede; Gerlant van Berlaer; Marc Raes; Helene Verhelst; Tine Boiy; Pierre Van Damme; Anna C Jansen; Marije Meuwissen; Vito Sabato; Guy Van Camp; Arvid Suls; Jutte Van der Werff Ten Bosch; Joke Dehoorne; Rik Joos; Kris Laukens; Pieter Meysman; Benson Ogunjimi
Journal:  Pediatr Rheumatol Online J       Date:  2022-10-17       Impact factor: 3.413

Review 3.  COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?

Authors:  Michael J Ombrello; Grant S Schulert
Journal:  Transl Res       Date:  2021-03-05       Impact factor: 7.012

4.  Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma.

Authors:  Antonia Pascarella; Claudia Bracaglia; Ivan Caiello; Alessia Arduini; Gian Marco Moneta; Marianna Nicoletta Rossi; Valentina Matteo; Manuela Pardeo; Fabrizio De Benedetti; Giusi Prencipe
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

5.  Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study.

Authors:  Junyu Liang; Heng Cao; Bowen Wu; Yinuo Liu; Ye He; Bei Xu; Yiduo Sun; Bingjue Ye; Jin Lin
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

6.  Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction.

Authors:  David T Teachey; Hamid Bassiri; Edward M Behrens; Caroline Diorio; Rawan Shraim; Laura A Vella; Josephine R Giles; Amy E Baxter; Derek A Oldridge; Scott W Canna; Sarah E Henrickson; Kevin O McNerney; Frances Balamuth; Chakkapong Burudpakdee; Jessica Lee; Tomas Leng; Alvin Farrel; Michele P Lambert; Kathleen E Sullivan; E John Wherry
Journal:  Nat Commun       Date:  2021-12-10       Impact factor: 17.694

7.  Analysis of chromatin data supports a role for CD14+ monocytes/macrophages in mediating genetic risk for juvenile idiopathic arthritis.

Authors:  Elizabeth A Crinzi; Emma K Haley; Kerry E Poppenberg; Kaiyu Jiang; Vincent M Tutino; James N Jarvis
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

8.  Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data.

Authors:  He Li; Meiqi Wei; Tianyuan Ye; Yiduan Liu; Dongmei Qi; Xiaorui Cheng
Journal:  Front Neurol       Date:  2022-09-20       Impact factor: 4.086

9.  IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome.

Authors:  Denny K Gao; Nathan Salomonis; Maggie Henderlight; Christopher Woods; Kairavee Thakkar; Alexei A Grom; Sherry Thornton; Michael B Jordan; Kathryn A Wikenheiser-Brokamp; Grant S Schulert
Journal:  JCI Insight       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.